John Budd
Rheumatology · Saint Louis, MONPI 1669425989
Payments from drug & device makers
Across 1,279 payments — averaging $316.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$122K
- AbbVie$102K
- Sun Pharmaceutical Industries Inc.$68K
- Gilead$65K
- GSK$21K
- EMD Serono, Inc.$6K
- plus $21K from 32 others
Across 13 payments — averaging $126.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1K
- Eli Lilly$479
What the payments were for
- Food & beverage$16,45399%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 18 | $122,127 |
| AbbVie | 198 | $101,856 |
| Sun Pharmaceutical Industries Inc. | 54 | $68,288 |
| Gilead | 32 | $64,652 |
| GSK | 80 | $20,811 |
| EMD Serono, Inc. | 2 | $5,882 |
| Astrazeneca AB | 1 | $5,350 |
| Pfizer | 159 | $3,956 |
| Amgen(2 entities) | 152 | $2,370 |
| Johnson & Johnson(2 entities) | 177 | $2,212 |
| E.r. Squibb & Sons, L.L.C. | 73 | $1,427 |
| UCB, Inc. | 80 | $1,238 |
| Novartis | 78 | $1,112 |
| AstraZeneca(2 entities) | 36 | $768 |
| Genentech USA, Inc. | 25 | $514 |
| Lilly USA, LLC | 32 | $514 |
| Sanofi | 8 | $219 |
| Aurinia Pharma U.S., Inc. | 11 | $194 |
| Bristol Myers Squibb | 19 | $154 |
| Janssen Scientific Affairs, LLC | 1 | $119 |
| Radius Health, Inc. | 5 | $110 |
| Boehringer Ingelheim | 5 | $97 |
| Pacira Therapeutics, Inc. | 5 | $75 |
| Organon | 3 | $68 |
| Medexus Pharma, Inc. | 4 | $54 |
| Antares Pharma, Inc. | 3 | $48 |
| Novo Nordisk | 3 | $43 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $38 |
| Fresenius Kabi USA, LLC | 2 | $30 |
| Sandoz | 2 | $28 |
| Merck | 2 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $21 |
| Biogen | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Sobi, Inc | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cimzia$123
- Tremfya$119
- KRYSTEXXA$117
- SAPHNELO$107
- ANORO ELLIPTA$101
How this compares
$404,486 in reported general payments places this provider in the 90th percentile of 134 rheumatology providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 18 | $916 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 14 | $334 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Saint Louis
- Alfred KimSaint Louis$1.2M
- Sona KamatSaint Louis$931K
- Akgun InceSaint Louis$849K
- Adam KilianSaint Louis$593K
- Chad RonholmSaint Louis$327K
- Reema SyedSaint Louis$313K
- Richard BrasingtonSaint Louis$110K
- Barbara CacioloSaint Louis$98K
- Deborah ParksSaint Louis$91K
- Joseph StauberSaint Louis$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.